/PZRXQ

PZRXQ Stock - PhaseRx, Inc.

Q: What is the analyst price target for PZRXQ?

Analyst price target information is not currently available for PZRXQ.

Q: What is PZRXQ's market cap?

Market capitalization information is not currently available for PZRXQ.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PZRXQ

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2014

FY2015

FY2016

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-2.55

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2016	FY2015	FY2014
Revenue	N/A	$375,000	$1.20M
Gross Profit	N/A	$375,000	$1.20M
Gross Margin	N/A	100.0%	100.0%
Operating Income	$-18,330,000	$-5,807,000	$-5,591,000
Net Income	$-20,137,000	$-7,377,000	$-6,849,000
Net Margin	N/A	-1967.2%	-570.8%
EPS	$-2.68	$-0.94	$-1.16

Company Overview

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.

Visit Website

Earnings History & Surprises

PZRXQ

Beat Rate

40%

Last 5 quarters

Avg Surprise

-43.7%

EPS vs Estimate

Beats / Misses

2/3

Last 12 quarters

Latest EPS

$-0.23

Q4 2017

EPS Surprise History

Q4 15

No data

Q1 16

No data

Q3 16

-195.0%

$-0.59vs$-0.20

Q4 16

-45.0%

$-0.29vs$-0.20

Q4 16

No data

Q2 17

-20.7%

$-0.35vs$-0.29

Q3 17

+14.3%

$-0.30vs$-0.35

Q4 17

+28.1%

$-0.23vs$-0.32

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2018	Mar 29, 2018	—	—	—	—
Q4 2017	Nov 9, 2017	$-0.32	$-0.23	+28.1%	✓ BEAT
Q3 2017	Aug 10, 2017	$-0.35	$-0.30	+14.3%	✓ BEAT
Q2 2017	May 12, 2017	$-0.29	$-0.35	-20.7%	✗ MISS
Q4 2016	Dec 31, 2016	—	$-0.30	—	—
Q4 2016	Nov 7, 2016	$-0.20	$-0.29	-45.0%	✗ MISS
Q3 2016	Aug 2, 2016	$-0.20	$-0.59	-195.0%	✗ MISS
Q1 2016	Mar 31, 2016	—	$-0.20	—	—
Q4 2015	Dec 31, 2015	—	$-0.23	—	—
Q3 2015	Sep 30, 2015	—	$-0.25	—	—
Q2 2015	Jun 30, 2015	—	$-0.22	—	—
Q1 2015	Mar 31, 2015	—	$-0.23	—	—